Correction to: Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial

J A Walsh; A B Gottlieb; B Hoepken; T Nurminen; P J Mease

doi:10.1007/s10067-018-4311-z

Correction to: Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial

Clin Rheumatol. 2018 Dec;37(12):3297. doi: 10.1007/s10067-018-4311-z.

Authors

J A Walsh¹, A B Gottlieb², B Hoepken³, T Nurminen³, P J Mease⁴

Affiliations

¹ Division of Rheumatology, University of Utah School of Medicine, Salt Lake City, UT, USA. jessica.walsh@hsc.utah.edu.
² Department of Dermatology, New York Medical College, Metropolitan Hospital, New York, NY, USA.
³ UCB Pharma, Monheim, Germany.
⁴ Swedish Medical Center and University of Washington, Seattle, WA, USA.

PMID: 30311014
DOI: 10.1007/s10067-018-4311-z

Abstract

The above article originally published with an error present in Discussion section and presented correctly in this article. The original article was corrected.

Publication types

Published Erratum